Gilbert Lynn Marks serves as Executive at AN2 Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Gilbert Lynn Marks has executed 3 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Jan 12, 2026 involved receiving (via award) 11,560 shares valued at $0.
Gilbert Lynn Marks currently holds 75,309 shares of AN2 Therapeutics, Inc. (ANTX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Gilbert Lynn Marks has been a net neutral trader of ANTX stock. They have purchased $0 and sold $0 worth of shares.
Gilbert Lynn Marks's most recent insider trade was on Jan 12, 2026, when they sold 11,560 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| Jul 10, 2025 | ANTX | $0 | Award | 11,875 | $N/A | Discretionary |